Prescription medication · Bisphosphonate
ibandronate
Also sold as Boniva. Ibandronate is used to treat and prevent osteoporosis in women after menopause.
Data updated 2026-05-15
- 2,935
- FDA reportsLightly reported
- 2
- InteractionsFew interactions
- $52.88
- Generic price (NADAC)
What the data shows
ibandronate (Boniva) is a prescription Bisphosphonate, among the least-reported drugs the FDA tracks (2,935 FDA reports), with 2 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
ibandronate (Boniva) is a prescription Bisphosphonate. Ibandronate is used to treat and prevent osteoporosis in women after menopause.
Ibandronate (Boniva) is a medicine that helps treat and prevent bone loss in women after menopause. It makes bones stronger and less likely to break.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Generic Price
$52.88/unit
Generic Available
Yes (9 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Ibandronate is used to treat and prevent osteoporosis in women after menopause.
Common side effects
Back pain, Upset stomach, Pain in arms or legs
Key warnings
This medicine can cause problems with your esophagus.
The sections below are summarized in plain English from ibandronate's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Ibandronate belongs to a class of drugs called bisphosphonates. It works by slowing down the breakdown of bone. This helps to increase bone density and reduce the risk of fractures.
How to Take It
Take one 150 mg tablet once a month, on the same day each month. Swallow the tablet whole with 6 to 8 ounces of plain water. Do this at least 60 minutes before you eat, drink, or take any other medicines. Do not lie down for at least 60 minutes after taking the tablet.
This is a plain-language summary of ibandronate's FDA labeling, not individualized dosing advice. Ask a pharmacist or prescriber before changing how you take this medication.
Pregnancy & Breastfeeding
Ibandronate is not for use in women who can get pregnant. It is not known if this medicine will harm an unborn baby. Talk to your doctor if you are breastfeeding.
This is a plain-language summary of ibandronate's FDA labeling, not individualized advice. Ask a pharmacist or prescriber about pregnancy or breastfeeding on this medication.
Missed Dose
If you miss your monthly dose, take it the next morning if your next dose is more than 7 days away. If your next dose is 1 to 7 days away, wait and take it on your next scheduled day.
This is a plain-language summary of ibandronate's FDA labeling, not individualized advice. Ask a pharmacist or prescriber what to do about your specific missed dose.
Storage
Store at room temperature, away from heat and moisture.
Side Effects (from patient reports)
Based on 2,935 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for ibandronate, by number of reports
- Joint pain
Joint pain
243 reports
- Diarrhea
Diarrhea
230 reports
- Feeling sick to your stomach
Feeling sick to your stomach
219 reports
- Broken thigh bone
Broken thigh bone
216 reports
- Headache
Headache
198 reports
- Tiredness
Tiredness
190 reports
- Falling down
Falling down
165 reports
- Feeling dizzy
Feeling dizzy
163 reports
- Pain
Pain
161 reports
- Weakness
Weakness
154 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for ibandronate each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where ibandronate sits
ibandronate has more FDA adverse-event reports than 18% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is ibandronate; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 2,935 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.
Total Reports
2,935
Reports Mentioning Death
274
9.3% of reports — not proof of cause
Hospitalization Reports
655
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | ARTHRALGIA | 243 |
| 2 | DIARRHOEA | 230 |
| 3 | NAUSEA | 219 |
| 4 | FEMUR FRACTURE | 216 |
| 5 | HEADACHE | 198 |
| 6 | FATIGUE | 190 |
| 7 | FALL | 165 |
| 8 | DIZZINESS | 163 |
| 9 | PAIN | 161 |
| 10 | ASTHENIA | 154 |
| 12 | MYALGIA | 140 |
| 13 | PAIN IN EXTREMITY | 139 |
| 14 | VOMITING | 138 |
| 15 | BACK PAIN | 132 |
| 16 | DYSPNOEA | 132 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
This medicine can cause problems with your esophagus. To help prevent this, follow the directions carefully and stay upright for at least 60 minutes after taking it. Rarely, serious bone, joint, or muscle pain can occur. Tell your doctor if you have new pain in your thigh or groin. Osteonecrosis of the jaw (bone damage in the jaw) has been reported.
Known Drug Interactions
Do not take within 60 minutes of dosing ( 7.1 ) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. 7.2 Aspirin/Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Because aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with ibandronate sodium tablets.
Mechanism: Both of these medicines can irritate your stomach and throat, which increases the chance of developing sores or pain.
What to do: Be very careful when taking these together and wait at least 60 minutes after taking ibandronate before taking aspirin.
7.3 H2 Blockers In healthy volunteers, co-administration with ranitidine resulted in a 20% increased bioavailability of ibandronate, which was not considered to be clinically relevant (see CLINICAL PHARMACOLOGY [12.3] ) . 7.3 H2 Blockers In healthy volunteers, co-administration with ranitidine resulted in a 20% increased bioavailability of ibandronate, which was not considered to be clinically relevant (see CLINICAL PHARMACOLOGY [12.3] ) .
Mechanism: Ranitidine increases the amount of ibandronate that is absorbed into your body.
What to do: No specific changes are usually needed because this increase is not expected to cause problems.
This is a plain-language summary of interactions documented in FDA labeling, not individualized advice. Ask a pharmacist or prescriber before combining medications.
Common Questions
Can I take ibandronate with food?
What should I do if I have heartburn after taking ibandronate?
Can I take calcium supplements with ibandronate?
What if I can't stand or sit upright for 60 minutes?
Does ibandronate interact with other medications?
How long should I take ibandronate?
What are the symptoms of osteonecrosis of the jaw?
What should I do if I experience severe bone, joint, or muscle pain?
Can ibandronate cause kidney problems?
What if I have trouble swallowing the tablet?
What are the common side effects of ibandronate?
Does ibandronate interact with other medications?
What drug class is ibandronate?
Is ibandronate safe during pregnancy?
Related Medications in Bisphosphonate
Other drugs grouped near ibandronate - same-class peers and common alternatives.
abaloparatide
Tymlos
Tymlos is a medicine to treat osteoporosis.
Compare with ibandronate →
alendronate
Fosamax
Binosto is a medicine that helps make your bones stronger.
Compare with ibandronate →
calcitonin
Miacalcin, Fortical
Calcitonin is a medicine that helps manage calcium levels in your body.
Compare with ibandronate →
denosumab
Prolia, Xgeva
Stoboclo is a medicine that helps to treat osteoporosis and increase bone mass.
Compare with ibandronate →
risedronate
Actonel
Risedronate sodium delayed-release tablets help treat osteoporosis after menopause.
Compare with ibandronate →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
Why some drugs demand precise dosing and monitoring
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on ibandronate
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for ibandronate
The FDA label for ibandronate (sold under brand names such as Boniva) classifies it as a prescription-only medication in the Bisphosphonate class. Ibandronate is used to treat and prevent osteoporosis in women after menopause. Official labeling lists 6 commonly reported side effects, including Back pain, Upset stomach, Pain in arms or legs.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 2,935 voluntary reports. The database also lists 2 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated major severity. NADAC pricing from CMS shows a generic unit cost of $52.88.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice, always consult a licensed healthcare provider before starting, stopping, or changing any medication.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.
Last updated: June 12, 2025
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled and last refreshed May 2026. See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages